Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

NCT03708003 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
30
Enrollment
OTHER
Sponsor class

Stopped The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.

Conditions

Interventions

Sponsor

Swiss Cancer Institute